Chemistry42

Insilico Medicine's AI-designed drug rentosertib, the first oral TNIK inhibitor to reach clinical trials, began Phase III testing on July 7, 2026, across 47 centers in China with approximately 320 pat…

Insilico Medicine's AI platform PandaOmics identified a novel pain target, leading to the discovery of ISM9528, an oral, brain-penetrant, non-opioid candidate that outperformed morphine in preclinical…

Insilico Medicine announced on July 29 that the U.S. FDA granted Fast Track Designation to its AI-designed pan-TEAD inhibitor ISM6331 for adults with unresectable malignant pleural mesothelioma after …